The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantation

Xenotransplantation

Volumn 17, Issue 1, 2010, Pages 3-5

  Ezzelarab, Mohamed ^a   Ayares, David ^b   Cooper, David K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b REVIVICOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTIINFLAMMATORY AGENT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CHRONIC ALLOGRAFT NEPHROPATHY; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY ALLOGRAFT; KNOCKOUT GENE; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; NOTE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SWINE; T LYMPHOCYTE; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; MESENCHYMAL STEM CELLS; STROMAL CELLS; SUS SCROFA; TRANSPLANTATION, HETEROLOGOUS;

EID: 76349090924     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2009.00567.x     Document Type: Note

References (12)

1. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008 57 : 1759.
2. Sordi V. Mesenchymal stem cell homing capacity. Transplantation 2009 87 : S42.
3. Dahlke M, Hoogduijn M, Eggenhofer E et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009 88 : 614.
4. Popp FC, Eggenhofer E, Renner P et al. Mesenchymal stem cells can affect solid organ allograft survival. Transplantation 2009 87 : S57.
5. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004 363 : 1439.
6. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008 371 : 1579.
7. Bartmann C, Rohde E, Schallmoser K et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007 47 : 1426.
8. Davani B, Ikonomou L, Raaka BM et al. Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 2007 25 : 3215.
9. Henriksson HB, Svanvik T, Jonsson M et al. Transplantation of human mesenchymal stems cells into intervertebral discs in a xenogeneic porcine model. Spine (Phila Pa 1976) 2009 34 : 141.
10. Shabbir A, Zisa D, Leiker M, Johnston C, Lin H, Lee T. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation 2009 87 : 1275.
11. Solari MG, Srinivasan S, Boumaza I et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 2009 32 : 116.
12. Brusko TM. Mesenchymal stem cells: a potential border patrol for transplanted islets? Diabetes 2009 58 : 1728.